1 dollar question, page-2

It is the million dollar question Pixie & while not game to make any assumptions with any certainty at an early stage the ticket rests with FDA based on the outcome.

Much like Carfilzomib gained Accelerated Approval from the FDA allowing it to be in market on Phase II data whilst Phase III trials ran concurrently the opportunity is always there but of course without any certainty.

Onyx acquired Proteolix in 2011 for Carfilzomib whilst in Phase II trials - $276M upfront, $540M in milestones by the time it gets to market and a WHOPPING $176M bonus IF it was able to secure Accelerated Approval from the FDA which it did. Sounds like a lot of money but when you then look at how much Amgen paid for Onyx basically weighted on Kyprolis then it was a super move.

Anyway who knows but a lot will rest in how the combination trial delivers and any additional stamps the FDA bring forward.